Loading...
Market
What will be Gilead Sciences' total revenue for full-year 2024?
2
Resolution / Starting Odds
Below $27.1 billion • 25%
$27.1 billion to $27.3 billion • 25%
$27.31 billion to $27.5 billion • 25%
Above $27.5 billion • 25%
Gilead Sciences' full-year 2024 financial report
Story
Gilead Sciences Q2: EPS $2.01, Revenue $6.95B, Raises Full-Year Outlook
Aug 12, 2024, 11:02 AM
Gilead Sciences reported its second-quarter 2024 financial results, significantly surpassing Wall Street estimates. The company achieved a revenue of $6.95 billion, exceeding the estimated $6.72 billion, marking a 5% year-over-year increase. The earnings per share (EPS) stood at $2.01, surpassing the forecasted $1.60, reflecting a 50% year-over-year growth. This performance was driven by higher product sales, particularly in HIV, liver disease, and oncology segments. Biktarvy sales reached $3.23 billion, while Veklury sales were $214 million. Additionally, Gilead raised its full-year earnings outlook, projecting adjusted EPS between $3.60 and $3.90, compared to the previous range of $3.45 to $3.85. The company's market capitalization is reported at $94 billion.
View original story
Similar markets
Less than $100B • 25%
$100B to $150B • 25%
$150B to $200B • 25%
More than $200B • 25%
Less than $3 billion • 25%
$3 billion to $3.5 billion • 25%
$3.5 billion to $4 billion • 25%
More than $4 billion • 25%
Below $2.4 billion • 25%
$2.4 billion to $2.5 billion • 25%
$2.5 billion to $2.6 billion • 25%
Above $2.6 billion • 25%
Below $45 billion • 25%
$45 billion to $45.5 billion • 25%
$45.5 billion to $46 billion • 25%
Above $46 billion • 25%
$45.4 billion to $46.6 billion • 25%
Less than $45.4 billion • 25%
More than $46.6 billion • 25%
Between $46.0 billion and $46.6 billion • 25%
Biotech Company • 25%
Pharmaceutical Company • 25%
Medical Device Company • 25%
No major acquisition • 25%
Less than $85 billion • 25%
$85 billion to $90 billion • 25%
$90 billion to $95 billion • 25%
More than $95 billion • 25%
Less than $300M • 33%
$300M - $500M • 33%
More than $500M • 33%
Below $200 billion • 25%
$200 billion - $220 billion • 25%
$220 billion - $240 billion • 25%
Above $240 billion • 25%